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Background: Avian influenza A (H5N1) in human presents a global pandemic threat, and
preparedness is urgently required in high-risk countries.
Methods: A retrospective chart review was conducted on 8 patients with H5N1
infection (aged 2–30 years; 3 fatal) who were hospitalized in Bach Mai Hospital
(BMH), Vietnam, or in affiliated hospitals with consultation by physicians in BMH
between 2007 and 2010. Demographic background, chest radiographs, and clinical
and laboratory data were evaluated to determine the critical issues in relation to
clinical outcomes. Treatment of 4 patients with acute respiratory distress syndrome
(ARDS) (2 fatal) was assessed for renal replacement therapy using continuous
hemodiafiltration (CHDF), polymyxin B-immobilized (PMX) hemoperfusion, or their
combination.
Results: Patients had direct contact with dead/sick poultry infected with H5N1 virus or
lived in areas where H5N1 poultry outbreaks had been reported at the same time
as their illness. Time to initiation of oseltamivir from symptom onset was 2–6 days
for survivors and 7–9 days for non-survivors. All patients except one had infiltrative
shadows on chest radiographs on admission. Patients with delayed treatment
developed ARDS. Renal replacement therapy contributed to patient survival, with
improvement of oxygenation and a dramatic decrease in serum cytokine levels if initiated
earlier.
Conclusions: Understanding local H5N1 poultry outbreaks and chest radiography assist
early diagnosis and initiation of antiviral treatment. Developing a network among local
and tertiary care hospitals can reduce the time to initiation of treatment. CHDF and PMXpanese Respiratory Society. Published by Elsevier B.V. All rights reserved.
distress syndrome; ALI, acute lung injury; CHDF, continuous hemodiafiltration;
rferon; IL, interleukin; TNF, tumor necrosis factor; FiO2, fraction of inspired oxygen;
blood; P/F, PaO2/FiO2; SOFA, Sequential Organ Failure Assessment
sity, Suite 613-6, #19 Build, 1-21-1 Nishi-Waseda, Shinjuku-ku, Tokyo 169-0051, Japan.
. Kudo).
Fig. 1 – Map of Vietnam indicating the
infection. Light gray area indicates the h
r e s p i r a t o r y i n v e s t i g a t i o n 5 0 ( 2 0 1 2 ) 1 4 0 – 1 5 0 141hemoperfusion are possible candidates for effective treatment of ARDS with H5N1 if
applied earlier.
& 2012 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Avian influenza A (H5N1) virus infection in human presents a
global pandemic threat. To date, H5N1 infection in human
has been sporadic and related to exposure to zoonotic
sources of the virus [1,2]. The recent unpredictable changes
in H5N1 virus in human highlight the urgent need for clinical
preparedness. H5N1 outbreaks among poultry and wild birds
have occurred in Japan and worldwide [3]. It is necessary to
implement a high alert for H5N1 in these high-risk countries.
H5N1 infection rapidly leads to severe pneumonia and
acute respiratory distress syndrome (ARDS), which are patho-
logically characterized as diffuse alveolar damage [4,5]. Osel-
tamivir treatment is recommended for H5N1 patients [6–8],
and the timing of antiviral treatment is vital for achieving a
positive outcome [6,9]. The development of a clinical treat-
ment system to administer oseltamivir as early as possible is
crucial for H5N1 patients. In addition, the optimal dosage and
duration of oseltamivir treatment need to be clarified for
H5N1 patients [10,11]. Single treatment with oseltamivir is
not sufficient for most H5N1 patients. Combination therapy
with antiviral agents seems to be needed for severe pneumo-
nia [2,11]. Without appropriate treatment for pneumonia due
to H5N1 infection, ARDS can develop and often leads to death
[4,12]. Since 2007, 30 confirmed human cases have been
reported in Vietnam to date (63.3% of mortality). Despite
the relatively low incidence of human H5N1 infections
globally, H5N1 infection has been occurring continuously,
with a high mortality rate [1]. This has rendered it difficult
to conduct clinical studies to find effective treatmentlocation of the study p
ealthcare network amostrategies. It has also resulted in a small number of physi-
cians who have the experience and knowledge to treat H5N1
patients. Therefore, additional clinical data need to be
collected.
The aims of the present study were to examine the clinical
backgrounds and treatment methods of patients with H5N1
infection in Vietnam and to assess how the clinical system
contributed to early initiation of oseltamivir treatment, how
treatment affected patient survival, and whether renal repla-
cement therapy was effective in H5N1 patients with ARDS.
Experience in treating H5N1 patients can contribute to
clinical preparedness for any future pandemic deriving from
highly pathogenic influenza virus infection.2. Materials and methods
2.1. Study site and subjects
Bach Mai Hospital (BMH) is a government hospital in Hanoi,
Vietnam, that has played a central role in treating H5N1
patients in northern Vietnam since 2003. BMH has developed
a cooperative network for treating H5N1 patients among
provincial and district hospitals in 19 provinces (Fig. 1).
Within the network, medical providers can exchange scien-
tific information relating to H5N1 infection and clinical
consultations by physicians in BMH who have treated H5N1
patients. The subjects of the present study were 8 patients
with H5N1 infection between 2007 and 2010 who were
hospitalized and treated in BMH (2 fatal), or hospitalized inatients, as well as month and year of occurrence of H5N1
ng 19 provinces in this study.
r e s p i r a t o r y i n v e s t i g a t i o n 5 0 ( 2 0 1 2 ) 1 4 0 – 1 5 0142local hospitals within the network and treated through
consultations with physicians in BMH (one fatal). All patients
tested positive for H5N1 virus by real-time reverse
transcriptase-polymerase-chain-reaction (RT-PCR) at the
National Institute of Hygiene and Epidemiology, Hanoi.
2.2. Study design
A retrospective chart review was conducted on 8 patients
with H5N1 infection. Demographic background, clinical data,
chest radiographs, and laboratory data were collected and
assessed to determine the critical issues for treating H5N1
patients in relation to clinical outcomes. Renal replacement
therapy was performed by using continuous hemodiafiltra-
tion (CHDF) [13], an absorbent column containing polymyxin
B fiber (Toraymyxin/PMX, Toray Medical Co., Ltd., Tokyo,
Japan) [14], or its combination, and was evaluated for treating
ARDS due to H5N1 infection in 4 patients who were treated in
the intensive care unit (ICU) of BMH. Partial pressure of
oxygen in arterial blood/fraction of inspired oxygen (P/F)
and Sequential Organ Failure Assessment (SOFA) score in 4
patients with ARDS as well as levels of serum inflammatory
cytokines in a patient treated with PMX hemoperfusion were
assessed at different time points during the ICU stay.
Hospital admission was defined as the time when treat-
ment for H5N1 infection was initiated. ARDS and acute lung
injury (ALI) were defined as P/Fr200 and 200–300, respec-
tively [15].
2.3. Ethics
Ethical approvals were provided by the institutional review
boards of Ministry of Health, Vietnam (No. 7998/BYT-K2DT,
December 2011) and the National Center for Global Health
and Medicine (No. 592, March 2011). Written informed con-
sent was obtained from study patients or their relatives.3. Results
3.1. General characteristics of study patients
Among the 8 patients (6 female, 2 male, aged 2–30 years)
examined, four were initially treated at local hospitals and
transferred and treated in the ICU, BMH. The remaining 4
patients were treated in local general hospitals (Fig. 1). The
characteristics and clinical presentation on admission of
each patient are shown in Table 1.
None of the patients had any underlying diseases. Two
patients were chicken traders and another 2 reported cooking
and eating infected (dead) poultry. One patient was a fish
farmer who handled dried bird excrement as feed. The
remaining 4 patients of young age (2, 8, 17, and 23 years
old) had no history of direct contact with either sick or dead
poultry; however, they lived in areas where H5N1 poultry
outbreaks had been reported at the same time as their illness.
All patients had fever (Z38.0 1C) at the time of admission.
Productive cough and dyspnea were common. Chest pain was
observed in 5 patients. Upon admission, all patients, except
Patient 5, had respiratory difficulty (median respiration rate,30 breaths/min; range, 25–36); low oxygen saturation in arter-
ial blood under oxygen administration with nasal, mask, or
mechanical ventilation; and abnormal breath sounds
(crackles) in the chest. Infiltration shadows on chest radio-
graphs indicating pneumonia were observed at hospital
admission for all patients except Patient 5. The primary
laboratory tests were performed on admission (Table 1).
Specific abnormalities in laboratory findings were not
observed, except for tendencies toward leukopenia in per-
ipheral blood and high levels of serum creatinine.3.2. Clinical course and treatment of study patients
The clinical course and treatment for each patient are shown
in Table 2. All patients, except Patient 5, sought primary
medical assistance (primary care) in the local community
before hospital admission. Time from symptom onset (fever)
to primary care ranged 2–7 days. Patients were transferred to
either a local general hospital or BMH, and treatment for
H5N1 infection was initiated in accordance with positive
results by RT-PCR. The time from primary care to hospital
admission ranged 0–5 days, and total duration from symptom
onset to initiation of treatment ranged 2–9 days.
ALI/ARDS was observed in all patients on admission,
except Patient 5. Multiple organ failure developed in all
non-survivors and 2 survivors during hospitalization.
Patients 1 and 4 (survivors), who had long hospitalization,
had nosocomial infections, as determined by sputum and
blood cultures. Bacterial co-infection was detected in the
sputum from Patient 2 on admission.
All patients were treated with oseltamivir, which is the only
available antiviral agent in Vietnam. The basic dosage of
oseltamivir was 150 mg/day in local general hospitals and
300 mg/day in BMH. The duration of treatment was 5–8 days,
or until the patient’s death. Other drug regimens and treat-
ments included antibiotics, corticosteroids, oxygen including
ventilation support, and renal replacement therapy including
blood purification therapy. Between presentation to primary
care and hospital admission, patients were empirically trea-
ted with antibiotics. Corticosteroids were administered to all
patients with pneumonia concomitantly with oseltamivir.
Antibiotics were administered during the entire treatment
period.3.3. Chest radiographs
Chest radiographs are shown upon admission (before oselta-
mivir administration), at the time of worst condition, and
during the recovery period in Fig. 2. With Patients 6, 7, and 8
(non-survivors), consolidation shadows rapidly expanded to
the entire lung fields within a few days after hospital admis-
sion (but were not critical at admission in Patients 6 and 7).
consolidation shadows for survivors eventually diminished,
although 2 patients exhibited exacerbated conditions after
admission. Patients 1, 4, 6, and 7 developed pneumothorax
during mechanical ventilation support.
Table 1 – Background and clinical characteristics of patients on admission.
Variable Survivors Non-survivors
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
General background
Year of illness 2007 2008 2010 2010 2010 2007 2008 2009
Place treated BMH Province Province BMH Province BMH BMH Province
Age (yr)/gender
(M/F)
30/M 8/F 17/F 25/F 2/F 22/F 27/M 23/F
Route of
exposure to
virus
Handling
chickens
Ate infected
chicken
Backyard poultry
died 5 days
before onset
Cooked and
ate infected
chicken
Epidemic outbreak
in poultry in
residential area
Fish farmer,
handled bird
excrement
Chicken trader,
handled dead
chickens
Epidemic outbreak
in poultry in
residential area
Underlying
disease
None None None None None None None None
Clinical presentation
Body
temperature (1C)
40.1 38.5 38.0 39.5 37.5 38.1 39.8 39.0
Primary signs
and symptoms
Fever, dyspnea,
cough, sputum,
chest pain
Fever, dyspnea,
cough, sputum,
chest pain
Fever, dyspnea,
cough, sputum
Fever,
dyspnea,
cough, chest
pain
Fever, cough Fever,
dyspnea,
cough, chest
pain
Fever, dyspnea,
cough, chest
pain
Fever, dyspnea,
cough, chest pain,
diarrhea
Respiration rate
( per min)
30 25 NA 30 25 36 30 36
Crackles þ þ þ þ NA þ þ þ
SpO2
a under
oxygen
administration
(L/min)
74% 99% 92% 90% No oxygen 65% 70% 79%
8 L mask 3 L nasal 5 L nasal 8 L mask 100% 9 L mask 100%
MV MV
PaO2/FiO2
b 119 NA NA 207 NA 38.4 32.8 NA
Abnormal
shadow on chest
radiographc
Unilateral mixed Unilateral
infiltration
Bilateral mixed Bilateral
mixed
Absence of
pneumonia
Bilateral mixed Bilateral
consolidation
Unilateral
consolidation
APACHE scored 23 NA NA 22 NA 24 32 NA
SOFAe 11 NA NA 9 NA 9 10 NA
Laboratory findingsf
Serum
creatinine
(mg/dL)
1.45 0.90 NA 0.90 NA 0.82 1.12 2.68
AST (U/L) 477 145 NA 94 NA 199 171 114
ALT (U/L) 131 66 NA 12 NA 45 36 32
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r e s p i r a t o r y i n v e s t i g a t i o n 5 0 ( 2 0 1 2 ) 1 4 0 – 1 5 01443.4. Evaluation of renal replacement therapy including
PMX hemoperfusion for ARDS due to H5N1 infection
As a therapy for ARDS, renal replacement therapy and/or
blood purification therapy were applied to Patients 1, 4, 6, and
7, who were treated in BMH, where CHDF/PMX treatments
were provided. The P/F ratios for Patients 1, 4, 6, and 7 were
o100 at the time of the initiation of renal replacement
therapy (Table 3). Patient 1 (survivor) and Patient 7 (non-
survivor) were treated with CHDF, and the time from ARDS
onset to CHDF was o20 h in Patient 1 and427 h in Patient 7.
Patient 6 (non-survivor) was treated with PMX hemoperfu-
sion, and the time from ARDS onset to PMX was 424 h.
Patient 4 (survivor) was treated with PMX hemoperfusion
followed by CHDF, and the time from ARDS to the initiation of
sequential therapy was 10–15 h.
The available data for the sequential therapy with PMX
hemoperfusion and CHDF in Patient 4 were assessed both
with oxygenation and the measurement of five kinds of
serum cytokine levels (interleukin [IL]-6, IL-8, interferon
[IFN]-g, IL-1b, tumor necrosis factor [TNF]-a) (Fig. 3). Immedi-
ately after ICU admission, the respiratory condition of Patient
4 rapidly deteriorated and the P/F ratio decreased to 43. PMX
hemoperfusion was applied sequentially using 3 columns at a
flow rate of 100 mL/min for 3 days. The P/F ratio increased to
128 at 24 h and to 203 at 3 days after the initiation of PMX
hemoperfusion. Among the 5 serum cytokines examined,
levels of IL-6, IL-8, and IFN-g markedly decreased at 24 h
after initiation of PMX hemoperfusion, whereas significant
elevation of IL-1b and TNF-a was not observed at the time of
initiation of PMX hemoperfusion (Fig. 3). Patient 4 was treated
with CHDF after PMX hemoperfusion for 4 days. The patient
was extubated and discharged 23 days after symptom onset.
No serious adverse events were observed during the renal
replacement therapy.4. Discussion
The present study revealed that early initiation of antiviral
treatment has a strong influence on the survival of patients
with H5N1 infection, and that the healthcare network can
assist in providing early medical intervention. Renal replace-
ment therapy including PMX hemoperfusion, especially
sequential therapy with PMX and CHDF, can be offered to
treat H5N1 patients with ARDS. However, the timing is also
crucial for a positive outcome.
Most human cases of avian influenza (H5N1) occur through
direct or indirect contact with poultry or contaminated
environments [16–18]. Previous reports from Vietnam, Thai-
land, Indonesia, and Cambodia have presented a relationship
between human cases of H5N1 infection and a history of
contact with sick and/or dead poultry [4,17,19]. In the present
study, among 8 patients admitted to hospitals within the
network (Fig. 1), some had direct contact with infected
poultry because of their work or life habits. Others had no
history of direct contact, but H5N1 outbreaks in poultry
around these patients’ residential areas were reported at
the same time as their illness. An association between
infection in wild birds and H5N1 outbreaks among poultry
Table 2 – Clinical course and treatment of study patients.
Variable Survivors Non-survivors
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8
Clinical time course
Days from
onset to
primary carea
3 3 3 3 2 4 4 7
Days from
onset to
hospital
admissionb
6 6 4 5 2 7 9 8
Days from
onset to
treatmentc
6 6 4 5 2 7 9 8
Days
hospitalized
26 13 10 23 10 5 3 2
Days from
onset to death
– – – – – 12 12 10
Clinical progression of organ dysfunction
Respiratory
failure on
admission
ARDS ALI ALI ARDS None ARDS ARDS ARDS
MOF (days
from
admission)
þ (day 1) None None þ (day 1) None þ (day 1) þ (day 1) NA
Bacterial infectiond
On admission ND Streptococcus
pneumoniae
ND ND ND ND ND ND
During
hospitalization
(Days from
admission)
Acinetobacter
(day 4)
ND ND Acinetobacter (day 5) ND ND ND NA
P. cepacia (day 7)
P. aeruginosa
(day 11)
Treatment
Oseltamivir
(duration: days)
300 mg/day (8) 150 mg/day (5) 150 mg/day (5) 300 mg/day (8) 75 mg/day (6) 300 mg/day
(5, to death)
300 mg/day
(3, to death)
150 mg/day
(2, to death)
Corticosteroid
(duration: days)
Hydrocortisone
300 mg/day (6)
Methylprednisolone
40 mg/day (1)
Methylprednisolone
80 mg/day (1)
Methylprednisolone
500 mg/day (4)
None Hydrocortisone
300 mg/day (5)
Hydrocortisone
200 mg/day (3)
Hydrocortisone
200 mg/day (3)
200 mg/day (1) 250 mg/day (2)
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H5N1 poultry outbreaks is around the Tet holiday (Lunar New
Year) festival in January or February [21]. The distribution,
trading, and consumption of chickens increase dramatically
during this period [22] because chicken is a traditional dish
for the celebration of Tet. Thus, the risk of H5N1 infection in
humans increases around that time [21]. Illness in the study
patients tended to be concentrated around the Tet festival.
Therefore, understanding H5N1 poultry outbreaks and tradi-
tional habits, festivals, and celebrations that increase chicken
consumption can aid in prediction of the time of occurrence
of human H5N1 infections. It may also assist physicians’
decision making for diagnosis and treatment if patients with
pneumonia are presented.
Although the time to seeking healthcare reflects patients’
knowledge about disease, socioeconomic difficulties, historical
habits, and the healthcare system in each country, most of the
previous studies in Vietnam documented a median duration
from symptom onset to hospitalization for 6 days [4,23–25]. The
WHO summarized 42 cases of H5N1 infection that were
reported to the WHO in 2010, the median duration between
symptom onset and hospital admission was 4 days (range 0–12)
[26]. The present study observed a median of 6 days (range 2–9)
from symptom onset to hospitalization (Table 2). The rangewas
2–6 days in survivors and 7–9 days in non-survivors. Based on
the findings of the present study, it appears that 6 days is the
critical period for patient survival. However, there were two
distinct reasons that led to delayed initiation of oseltamivir
treatment from symptom onset. In the present study, the
average intervals from symptom onset to first access to primary
care and from primary care to initiation of antiviral adminis-
tration were 3.6 days (range 2–7) and 2.3 days (range 0–5),
respectively (Table 2). Providing proper education to motivate
people towards early access to healthcare and developing a
network among the different healthcare settings that enables
the transfer of H5N1 (suspected) patients from primary to
tertiary care can shorten the total time interval to initiation of
oseltamivir treatment [27,28]. In addition, waiting to receive a
positive RT-PCR result for H5N1 virus leads to delayed diagnosis.
All patients, except Patient 5, had infiltrative shadows on their
chest radiographs on admission (Fig. 2). If a patient had a
contact history with infected poultry or an H5N1 poultry out-
break around their residential area, he/she had the opportunity
to receive early oseltamivir treatment even if the PCR result had
not been obtained.
Variable symptoms and signs of the early stage of illness have
been reported [4,12,17,18,23,24,29]. In the present study, lower
respiratory tract symptoms were predominant at the early
stage of disease. High fever, along with cough, was present in
all study patients at the beginning of illness. This indicated that
the viral infection began in the lower respiratory tract in most
patients in the present study. At the time of hospital admission,
all patients, except Patient 5, had already developed pneumo-
nia. Patients who did not receive any treatment for 47 days
from symptom onset (non-survivors) and in whom focal or
unilateral shadows on chest radiographs were observed on
admission rapidly progressed to severe conditions with bilateral
and diffuse shadows (Fig. 2). In contrast, patients who received
oseltamivir treatment by r6 days from symptom onset (survi-
vors) did not experience rapid progression (Fig. 2).
Fig. 2 – Chest radiographs of each patient upon admission (before oseltamivir administration), at the time of worst condition,
and during the recovery period. All patients except Patient 5 had extensive consolidation shadows in unilateral or bilateral
lung fields on admission. Patient 1: subcutaneous and mediastinal emphysema was observed (day 8). Patient 4:
consolidations were observed all over the right lung and pneumothorax in the right thorax (day 14). Patient 5: no obvious
shadows were observed on admission (day 2). The number of days from symptom onset.
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Table 3 – Condition of patients treated with renal replacement therapy.
Outcome Patient 1 Patient 4 Patient 6 Patient 7
Survived Survived Died Died
Renal replacement therapy
Method CHDFa PMX/CHDFb CHDFa PMXc
Days from symptom onset 7 6 10 10
APACHE II scored on ICU admission 23 22 24 32
Time from occurrence of ARDSe to treatment (h) o20 10–15 427 424
MOFf at the time of initiation of treatment Yes Yes Yes Yes
P/F ratiog from the initiation of treatment
At the time of initiation 65 43 38 47
1 day 119 128 47 53
2 days 102 162 43 39
3 days 130 203 NA NA
SOFAh
At the time of initiation 10 13 11 9
1 day 8 10 12 13
2 days 7 11 NA NA
3 days 7 11 Death Death
ARDS, acute respiratory distress syndrome; NA, not available due to patient’s death.
a Continuous hemodiafiltration.
b Sequential therapy with PMX hemoperfusion (3 columns, for 3 days) and CHDF.
c Polymyxin B fiber column.
d APACHE II score [20].
e ARDS was considered to be present if PaO2/FiO2 o200.
f MOF: ARDS with oliguria in Patient 1, shock and coagulopathy in Patient 4, shock and coagulopathy in Patient 6, shock in Patient 7.
g P/F: PaO2/FiO2 ratio; PaO2: partial pressure of oxygen in arterial blood (mmHg); FIO2: fraction of inspired oxygen.
h SOFA, Sequential Organ Failure Assessment.
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patient at the time of admission. Nosocomial bacterial infec-
tions were found in 2 survivors. Secondary bacterial infection
was not detected in non-survivors. All non-survivors had
developed ARDS at the time of hospital admission and were
dead within 2–5 days following admission. It was not clear if
secondary bacterial infection developed between the onset of
illness and death under treatment with multiple antibiotics.
Antibiotics were administered to all patients. However, once
viral infection has been diagnosed, antibiotics administration
should be limited appropriately to reduce the incidence of
nosocomial bacterial infections, which are partly caused by
the large amount or variety of antibiotics.
Although the WHO recommends against administering
systemic corticosteroids, except for septic shock with adrenal
insufficiency [6–8], systemic corticosteroids were adminis-
tered to survivors and non-survivors in the present study,
with the exception of the patient without pneumonia. The
dose of corticosteroids for survivors and non-survivors did
not differ significantly, whereas the time to initiation of
corticosteroid treatment from symptom onset was later in
non-survivors than in survivors. The results suggest that
corticosteroid treatment did not negatively affect survivors
who received oseltamivir earlier and who had less severe
pneumonia than the non-survivors did. Therefore, the timing
appears to be crucial for obtaining clinical benefits from
corticosteroid treatment of H5N1 patients. However, further
investigations and discussions are required.
Four out of 8 patients developed ARDS and received renal
replacement therapy using CHDF, PMX hemoperfusion, orboth sequentially in the ICU at BMH (Table 3). PMX column is
a medical device initially developed to bind blood endotoxin
in sepsis caused by gram-negative bacilli [14]. PMX hemoper-
fusion can effectively improve the P/F ratio and mortality rate
[14,30,31]. Furthermore, a report on an animal model indi-
cated that PMX hemoperfusion could improve the oxygena-
tion associated with non-endotoxic lung injury and reduce
the serum level of IL-8 [32]. Hypercytokinemia is thought to
be one of the main causes of severe pneumonia associated
with influenza (H5N1) virus infection [5,6,33]. PMX hemoper-
fusion and CHDF can both reduce plasma cytokine levels
[30,31] and absorb activated neutrophils [34,35]. In addition,
PMX hemoperfusion improves hemodynamics [31,36,37].
There has been no report on H5N1 patient who was treated
with PMX. Some successful cases of ARDS with influenza
A(H1N1)pdm09 infection treated with PMX have been
reported in Japan [38,39], including evaluation of blood
cytokine levels [40]. In the present study, Patient 4 was treated
with PMX columns and sequential CHDF (Fig. 3). At 24 h after
initiation of PMX hemoperfusion, levels of IL-6, IL-8, and IFN-
g in the peripheral blood had markedly decreased, with
improvement of the P/F ratio. We believe that the improved
P/F ratio was a reflection of decreased serum cytokine levels,
which resulted in suppression of the inflammatory mechan-
ism for ARDS in the lungs by PMX hemoperfusion.
The previous reports have indicated that early initiation of
PMX hemoperfusion in patients with ALI and in patients with
abdominal septic shock improves pulmonary oxygenation
[35,41]. In the present study, patients treated with PMX
hemoperfusion within 20 h from the time of ARDS onset
Fig. 3 – Clinical course of Patient 4 receiving sequential therapy with PMX and CHDF. The P/F ratio increased from 43 to 128 at
24 h and to 203 after 3 days, and serum levels of IL-6, IL-8, and IFN-c markedly decreased 24 h after initiation of PMX
hemoperfusion. No significant elevation in IL-1b and TNF-a was observed at the time of initiation of PMX hemoperfusion.
Sequential CHDF maintained and improved the respiratory conditions of the patient.
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suggested that the early initiation of PMX hemoperfusion is
also crucial for the survival of patients with ARDS caused by
H5N1 infection. In addition, sequential CHDF maintained and
improved respiratory conditions in patients. PMX/CHDF treat-
ment appears to be a candidate for treating ARDS with H5N1
infection if applied early in the illness. To date, PMX columns
are only commercially available in Japan and Europe
[14,30,31]. Single treatment with CHDF can also contribute
to survival if PMX is not available (as in Patient 1). The results
were obtained from four patients, including evaluation of
blood cytokine levels in one patient, thus further investiga-
tion of the effect of PMX/CHDF on the treatment of H5N1
patients with ARDS is required.
The present study was limited by the small study population
of only eight patients. However, our experienceswith these cases
in Vietnam could contribute to clinical preparedness for severe
pneumonia with highly pathogenic avian influenza A (H5N1).5. Conclusions
Careful monitoring of local H5N1 poultry outbreaks, creating
a healthcare network, and using chest radiographs can
reduce the time to medical intervention for early diagnosis
and early initiation of antiviral treatment. Renal replacement
therapy using sequential therapy with PMX hemoperfusion
and CHDF are possible candidates for treating ARDS due to
H5N1 infection if applied early.Conflict of interest
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